Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies

ABSTRACT This study assesses the outcomes of immunotherapy discontinuation in patients with relapsing seronegative idiopathic myelitis (SIM), a condition that remains uninvestigated due to its rarity. We reviewed records from 77 patients with relapsing SIM at the National Cancer Center of Korea, foc...

Full description

Saved in:
Bibliographic Details
Main Authors: Ki Hoon Kim, You‐Ri Kang, Jae‐Won Hyun, Su‐Hyun Kim, Ho Jin Kim
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Annals of Clinical and Translational Neurology
Subjects:
Online Access:https://doi.org/10.1002/acn3.70063
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849771160173019136
author Ki Hoon Kim
You‐Ri Kang
Jae‐Won Hyun
Su‐Hyun Kim
Ho Jin Kim
author_facet Ki Hoon Kim
You‐Ri Kang
Jae‐Won Hyun
Su‐Hyun Kim
Ho Jin Kim
author_sort Ki Hoon Kim
collection DOAJ
description ABSTRACT This study assesses the outcomes of immunotherapy discontinuation in patients with relapsing seronegative idiopathic myelitis (SIM), a condition that remains uninvestigated due to its rarity. We reviewed records from 77 patients with relapsing SIM at the National Cancer Center of Korea, focusing on 11 who discontinued treatment after a median relapse‐free period of over 5 years. Notably, all patients remained relapse‐free for a median of 36.5 months following discontinuation. Our findings suggest that immunotherapy discontinuation can be a feasible therapeutic strategy for selected patients who have maintained a prolonged relapse‐free period.
format Article
id doaj-art-2d39178480ee461ebe784d0523a6ae06
institution DOAJ
issn 2328-9503
language English
publishDate 2025-08-01
publisher Wiley
record_format Article
series Annals of Clinical and Translational Neurology
spelling doaj-art-2d39178480ee461ebe784d0523a6ae062025-08-20T03:02:44ZengWileyAnnals of Clinical and Translational Neurology2328-95032025-08-011281689169210.1002/acn3.70063Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG AntibodiesKi Hoon Kim0You‐Ri Kang1Jae‐Won Hyun2Su‐Hyun Kim3Ho Jin Kim4Department of Neurology Severance Hospital, Yonsei University College of Medicine Seoul KoreaDepartment of Neurology Research Institute and Hospital of National Cancer Center Goyang KoreaDepartment of Neurology Research Institute and Hospital of National Cancer Center Goyang KoreaDepartment of Neurology Research Institute and Hospital of National Cancer Center Goyang KoreaDepartment of Neurology Research Institute and Hospital of National Cancer Center Goyang KoreaABSTRACT This study assesses the outcomes of immunotherapy discontinuation in patients with relapsing seronegative idiopathic myelitis (SIM), a condition that remains uninvestigated due to its rarity. We reviewed records from 77 patients with relapsing SIM at the National Cancer Center of Korea, focusing on 11 who discontinued treatment after a median relapse‐free period of over 5 years. Notably, all patients remained relapse‐free for a median of 36.5 months following discontinuation. Our findings suggest that immunotherapy discontinuation can be a feasible therapeutic strategy for selected patients who have maintained a prolonged relapse‐free period.https://doi.org/10.1002/acn3.70063discontinuationimmunotherapymyelitis
spellingShingle Ki Hoon Kim
You‐Ri Kang
Jae‐Won Hyun
Su‐Hyun Kim
Ho Jin Kim
Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies
Annals of Clinical and Translational Neurology
discontinuation
immunotherapy
myelitis
title Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies
title_full Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies
title_fullStr Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies
title_full_unstemmed Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies
title_short Discontinuation of Immunotherapy in Patients With Relapsing Myelitis Without AQP4/MOG Antibodies
title_sort discontinuation of immunotherapy in patients with relapsing myelitis without aqp4 mog antibodies
topic discontinuation
immunotherapy
myelitis
url https://doi.org/10.1002/acn3.70063
work_keys_str_mv AT kihoonkim discontinuationofimmunotherapyinpatientswithrelapsingmyelitiswithoutaqp4mogantibodies
AT yourikang discontinuationofimmunotherapyinpatientswithrelapsingmyelitiswithoutaqp4mogantibodies
AT jaewonhyun discontinuationofimmunotherapyinpatientswithrelapsingmyelitiswithoutaqp4mogantibodies
AT suhyunkim discontinuationofimmunotherapyinpatientswithrelapsingmyelitiswithoutaqp4mogantibodies
AT hojinkim discontinuationofimmunotherapyinpatientswithrelapsingmyelitiswithoutaqp4mogantibodies